PMID- 29277498
OWN - NLM
STAT- MEDLINE
DCOM- 20190423
LR  - 20211204
IS  - 1528-3933 (Electronic)
IS  - 1091-8531 (Linking)
VI  - 22
IP  - 1
DP  - 2018 Feb
TI  - Retinal astrocytoma regression in tuberous sclerosis patients treated with 
      everolimus.
PG  - 76-79
LID - S1091-8531(17)30436-6 [pii]
LID - 10.1016/j.jaapos.2017.08.009 [doi]
AB  - Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR) that has 
      been approved by the US Food and Drug Administration for the treatment of 
      subependymal giant cell astrocytoma (SEGA) in patients with tuberous sclerosis 
      complex (TSC). Retinal hamartomas, which are one of the major diagnostic features 
      of TSC, tend to remain stable or gradually progress in the natural history of the 
      disease. We report 2 patients with TSC treated with everolimus for SEGA in whom 
      fundus photographs and spectral domain optical coherence tomography demonstrated 
      regression of previously documented multiple retinal hamartomas in all 4 eyes.
CI  - Copyright (c) 2017 American Association for Pediatric Ophthalmology and Strabismus. 
      Published by Elsevier Inc. All rights reserved.
FAU - Zipori, Anat Bachar
AU  - Zipori AB
AD  - Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, 
      Toronto, Canada; Faculty of Medicine, University of Toronto, Toronto, Canada; 
      Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
FAU - Tehrani, Nasrin N
AU  - Tehrani NN
AD  - Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, 
      Toronto, Canada; Faculty of Medicine, University of Toronto, Toronto, Canada.
FAU - Ali, Asim
AU  - Ali A
AD  - Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, 
      Toronto, Canada; Faculty of Medicine, University of Toronto, Toronto, Canada. 
      Electronic address: asim.ali@sickkids.ca.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20171219
PL  - United States
TA  - J AAPOS
JT  - Journal of AAPOS : the official publication of the American Association for 
      Pediatric Ophthalmology and Strabismus
JID - 9710011
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Agents/*therapeutic use
MH  - Astrocytoma/*drug therapy
MH  - Child, Preschool
MH  - Everolimus/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Retinal Neoplasms/*drug therapy
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
MH  - Treatment Outcome
MH  - Tuberous Sclerosis/*complications
EDAT- 2017/12/27 06:00
MHDA- 2019/04/24 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/05/31 00:00 [received]
PHST- 2017/07/21 00:00 [revised]
PHST- 2017/08/14 00:00 [accepted]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2019/04/24 06:00 [medline]
PHST- 2017/12/27 06:00 [entrez]
AID - S1091-8531(17)30436-6 [pii]
AID - 10.1016/j.jaapos.2017.08.009 [doi]
PST - ppublish
SO  - J AAPOS. 2018 Feb;22(1):76-79. doi: 10.1016/j.jaapos.2017.08.009. Epub 2017 Dec 
      19.